Business Context and Reporting Period
Ascendis Pharma A/S, a foreign private issuer, filed this Form 6-K on March 17, 2026. The filing reports positive Week 52 topline results from the New InsiGHTS Phase 2 randomized, open-label, active-controlled trial in the U.S. The study investigated the safety, tolerability, and efficacy of once-weekly TransCon hGH (lonapegsomatropin) compared to daily somatropin in prepubertal children with Turner syndrome.
Key Financial Metrics
The filing text does not provide specific financial data, including revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on clinical trial results.
Material Changes and Clinical Results
The filing details the following outcomes from the New InsiGHTS trial involving 49 children aged 1 to 10 years:
- Efficacy: At Week 52, TransCon hGH demonstrated improved annualized height velocity (AHV) similar to daily somatropin. The least squares (LS) mean AHV was 9.05 cm/year for TransCon hGH versus 9.04 cm/year for daily somatropin.
- Dosing: The mean dose for TransCon hGH was 0.22 mg/kg/week, compared to 0.29 mg/kg/week for the daily somatropin cohort.
- Safety: TransCon hGH showed a safety and tolerability profile similar to daily somatropin through up to 143 weeks of follow-up. Adverse events were mild to moderate, with no discontinuations due to adverse events and no occurrences of slipped capital femoral epiphysis (SCFE).
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future financial performance, or specific risk factors beyond the clinical context. The primary outlook is positive regarding the clinical efficacy and safety of lonapegsomatropin for the treatment of Turner syndrome in prepubertal children.
Investor Verification Checklist
- Verify the full statistical analysis of the New InsiGHTS trial data, particularly regarding the non-inferiority margins for AHV.
- Confirm the regulatory pathway and timeline for FDA approval of TransCon hGH for Turner syndrome based on these Phase 2 results.
- Review the company's upcoming financial reports for any impact of this clinical success on revenue projections or R&D expense guidance.
- Assess the competitive landscape for growth hormone treatments in the pediatric Turner syndrome market.